Dengue Treatment Market size was valued at 635.68 Million in 2021 and is estimated to reach 3117.07 Million by 2028, at a CAGR of 25.5% during the forecast period 2022 to 2028. Dengue fever is also known as break bone fever is mosquito born and endemic disease that leads to severe flu like illness. Dengue caused by RNA virus dengue belongs to the family Flaviviridae. Dengue is spread by several species of mosquitos of the Aedes type, principally A. aegypti. Symptoms of dengue include fever, headache vomiting, muscle and joint pains, and characteristic skin rash. On infection of dengue, patient will automatically recover within seven days. But in some cases, it may develop to life threatening dengue hemorrhagic fever. The virus has five different types of strains, infection with one strain usually gives lifelong immunity to that type. Subsequent infection with a different type of dengue virus increases the risk of severe complications. Dengue Treatment market is expected to grow at a significant rate during forecast period. According to World Health Organization (WHO) estimates, 50 to 100 Mn infections occur annually, including 500,000 DHF cases and 22,000 deaths, mostly among children. Dengue treatment market is at developing stage. Market players collaborating to other companies or research institutions for the development of drugs for treating the dengue. For instance, in August 2013, Johnson and Johnson Services Inc. collaborated with biotechnology nonprofit organization The Wellcome Trust, for the development of prevention and treatment therapies for dengue fever.